Table 2.
Phase I/II Ultra-hypofractionation trials: Schedules and equivalent total doses in 2 Gy fractions
| Total Equivalent Dose in 2 Gy fractions (EQD2) |
≥ Grade 2 Late Toxicity (%) |
||||||
|---|---|---|---|---|---|---|---|
| REFERENCE | No. PTS | Dose/fx size/# fxs | α/β = 1.5 (tumor) |
α/β = 3 (late effects) |
Med. F/U (mo.) |
GI | GU |
| Madsen et al30 Virginia Mason |
40 | 33.5 Gy/6.7 Gy/5 fx | 78 Gy | 64.9 Gy | 41 | 7.5 | 20 |
| King et al41 Stanford |
41 | 36.25 Gy/7.25 Gy/5 fx | 90.6 Gy | 74.3 Gy | 33 | 15 | 29 |
| Widmark (personal communication, 2008) Umea |
105 | 42.7 Gy/6.1 Gy/7 fx | 92.7 Gy | 77.7 Gy | --- | --- | --- |
| Tang et al31 Univ. Toronto |
30 | 35 Gy/7 Gy/5 fx | 85.1 Gy | 70 Gy | 12 | 13 | 13 |
| Timmerman (personal communication, 2008) |
15 10 (ongoing) --- |
47.5 Gy/9.5 Gy/5 fx 50 Gy/10 Gy/5 fx 52 .5 Gy/10.5 Gy/5 fx |
149 Gy * 164 Gy 180 Gy |
118 Gy 130 Gy 142 Gy |
---- | --- | |
*
NTD calculations are based upon standard linear quadratic modeling, which may over predict NTD doses for large fraction sizes such as used in the UTSW trial.